Protocol Ledger

NCT03744910 · Phase III · TERMINATED

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Interventional Phase III clinical trial protocol NCT03744910 sponsored by CSL Behring in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-14 Enrollment: 194 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03744910
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)194 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03744910
Protocol FieldVerified Registry Value
NCT IdentifierNCT03744910
Consolidated Lead SponsorCSL Behring
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment194 participants (ACTUAL)
Registered Start Date2019-10-14
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI